v3.26.1
Segment Reporting - Summary of Segment Net Loss Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Revenue $ 102,484 $ 62,043
Restructuring and related costs (53,415)  
Operating expenses (260,851) (300,496)
Loss from operations (158,367) (238,453)
Non-cash interest expense related to the sale of future royalties (38,208) (31,070)
Interest income 9,251 18,643
Interest and other (income) expense, net (3,855) 25,782
Loss before provision for income taxes (191,179) (225,098)
Income tax expense 93 (2,363)
Adjustments and reconciling items 0 0
Net loss (191,086) (227,461)
Operating Segment    
Segment Reporting Information [Line Items]    
Revenue 102,484 62,043
Personnel-related expenses (81,114) (107,916)
Outside services (75,686) (105,056)
Preclinical research and clinical development expenses (6,680) (35,217)
Laboratory supplies (9,962) (15,547)
Facility and maintenance expenses (15,049) (16,030)
Equipment and office-related expenses (18,120) (19,216)
Travel-related expenses (825) (1,514)
Restructuring and related costs (53,415)  
Operating expenses (260,851) (300,496)
Loss from operations (158,367) (238,453)
Non-cash interest expense related to the sale of future royalties (38,208) (31,070)
Interest income 9,251 18,643
Interest and other (income) expense, net (3,855) 25,782
Non-operating income (32,812) 13,355
Loss before provision for income taxes (191,179) (225,098)
Income tax expense 93 (2,363)
Net loss $ (191,086) $ (227,461)